Anuncia Medical is a medical device company based in Scottsdale, Arizona. The team at Anuncia is on a mission to change how cerebrospinal fluid (CSF) is managed for patients living with conditions like hydrocephalus.
Working to improve outcomes and quality of life for patients living with hydrocephalus and other neurologic conditions by reducing device failures through innovative, non-invasive cerebrospinal fluid (CSF) management technologies.
Anuncia Medical, Inc. is a medical device company based in Scottsdale, Arizona. The team at Anuncia is on a mission to change how cerebrospinal fluid (CSF) is managed for patients living with conditions like hydrocephalus. Through its innovative ReFlow® platform, the company is tackling one of the most serious challenges patients face: shunt and catheter blockages. These blockages are not only common but can be life-threatening, often leading to repeated brain surgeries. Anuncia’s goal is to help reduce those risks and improve the quality of life for patients and their families.
Hydrocephalus occurs when excess cerebrospinal fluid builds up in the brain. If that fluid cannot drain properly, pressure rises, the brain can swell, and without treatment, it can lead to brain injury or death. Today, the standard of care relies on implanted shunts or temporary ICU drains called external ventricular drains (EVDs), both of which can become blocked without warning.
Anuncia’s technology is designed to address this critical and often overlooked failure point in patient care.
The Health Challenge Anuncia Is Addressing:
Anuncia Medical focuses on preventing and managing blockages in the small tubes inside shunts and external ventricular drains (EVDs) that help remove excess cerebrospinal fluid from the brain. When these tubes clog, pressure can rise rapidly, turning a routine treatment into a medical emergency that often requires urgent hospitalization or surgery.
Hydrocephalus affects more than one million people in the United States, with roughly 40,000 shunt procedures and 100,000 EVDs used each year. When these devices fail, patients may experience severe headaches, nausea, vomiting, extreme fatigue, and other alarming symptoms, placing immense emotional and physical strain on patients, families, and caregivers.
In Arizona and surrounding states, Valley Fever (Cocci) meningitis can further increase the risk of catheter blockages, especially among vulnerable populations. This includes children, older adults, veterans, and patients recovering from stroke, traumatic brain injury, infection, or tumors, making reliable CSF management even more critical in the region.
How Anuncia Is Making an Impact:
Anuncia’s ReFlow® platform is designed to help keep drainage pathways open non-invasively, allowing for earlier intervention and reducing avoidable device failures.
The ReFlow® Mini Flusher, which is FDA-cleared, can provide symptom relief when a blockage is forming and offers tactile feedback that the catheter is open. This simple but elegant innovation gives patients and caregivers greater confidence, peace of mind, and control, while potentially avoiding emergency procedures.
